Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$2.77M$2.77M+48.0% vs Q2 2023 Net Income-$10.99M-$10.99MN/M vs Q2 2023 EPS Diluted-$0.15-$0.15N/M vs Q2 2023 Operating Income-$12,854,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,308,000N/M Margins · derivedOperating margin-464.7%+1237.5 pt vs Q2 2023
Net margin-397.2%+1184.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end